DOCSLIB.ORG

Hematopoietic Cell Transplantation, Version 2.2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hematopoietic Cell Transplantation, Version 2.2020 NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Hematopoietic Cell Transplantation, Version 2.2020 Ayman Saad, MD1,*; Marcos de Lima, MD2,*; Sarah Anand, MD3; Vijaya Raj Bhatt, MBBS4,*; Ryan Bookout, PharmD5; George Chen, MD6,*; Daniel Couriel, MD, MS7; Antonio Di Stasi, MD8; Areej El-Jawahri, MD9; Sergio Giralt, MD10; Jonathan Gutman, MD11; Vincent Ho, MD12; Mitchell Horwitz, MD13; Joe Hsu, MD14; Mark Juckett, MD15; Mohamed Kharfan Dabaja, MD16,*; Alison W. Loren, MD, MSCE17; Javier Meade, MD18; Marco Mielcarek, MD, PhD19,*; Jonathan Moreira, MD20; Ryotaro Nakamura, MD21; Yago Nieto, MD, PhD22; Julianna Roddy, PharmD, BCOP1,*; Gowri Satyanarayana, MD23; Mark Schroeder, MD24,*; Carlyn Rose Tan, MD25; Dimitrios Tzachanis, MD, PhD26; Jennifer L. Burns27; and Lenora A. Pluchino, PhD27 ABSTRACT NCCN CATEGORIES OF EVIDENCE AND CONSENSUS Category 1: Based upon high-level evidence, there is uniform Hematopoietic cell transplantation (HCT) involves the infusion of hema- NCCN consensus that the intervention is appropriate. topoietic progenitor cells into patients with hematologic disorders with Category 2A: Based upon lower-level evidence, there is uniform the goal of re-establishing normal hematopoietic and immune function. NCCN consensus that the intervention is appropriate. HCT is classified as autologous or allogeneic based on the origin of he- ’ Category 2B: Based upon lower-level evidence, there is NCCN matopoietic cells. Autologous HCT uses the patient sowncellswhile consensus that the intervention is appropriate. allogeneic HCT uses hematopoietic cells from a human leukocyte antigen-compatible donor. Allogeneic HCT is a potentially curative Category 3: Based upon any level of evidence, there is major treatment option for patients with certain types of hematologic malig- NCCN disagreement that the intervention is appropriate. nancies, and autologous HCT is primarily used to support patients under- All recommendations are category 2A unless otherwise going high-dose chemotherapy. Advances in HCT methods and supportive noted. care in recent decades have led to improved survival after HCT; however, disease relapse and posttransplant complications still commonly occur Clinical trials: NCCN believes that the best management of in both autologous and allogeneic HCT recipients. Allogeneic HCT re- any patient with cancer is in a clinical trial. Participation in cipients may also develop acute and/or chronic graft-versus-host clinical trials is especially encouraged. disease (GVHD), which results in immune-mediated cellular injury of sev- PLEASE NOTE eral organs. The NCCN Guidelines for Hematopoietic Cell Transplantation focus on recommendations for pretransplant recipient evaluation and the The NCCN Clinical Practice Guidelines in Oncology (NCCN ® management of GVHD in adult patients with malignant disease. Guidelines ) are a statement of evidence and consensus of the authors regarding their views of currently accepted appro- J Natl Compr Canc Netw 2020;18(5):599–634 aches to treatment. Any clinician seeking to apply or consult doi: 10.6004/jnccn.2020.0021 the NCCN Guidelines is expected to use independent medi- cal judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National ® ® 1The Ohio State University Comprehensive Cancer Center - James Cancer Comprehensive Cancer Network (NCCN ) makes no repre- Hospital and Solove Research Institute; 2Case Comprehensive Cancer Center/ sentations or warranties of any kind regarding their content, University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig use, or application and disclaims any responsibility for their Cancer Institute; 3University of Michigan Rogel Cancer Center; 4Fred & Pamela application or use in any way. Buffett Cancer Center; 5Moffitt Cancer Center; 6Roswell Park Comprehensive © National Comprehensive Cancer Network, Inc. 2020. All Cancer Center; 7Huntsman Cancer Institute at the University of Utah; 8O’Neal rights reserved. The NCCN Guidelines and the illustrations Comprehensive Cancer Center at UAB; 9Massachusetts General Hospital herein may not be reproduced in any form without the express 10 11 Cancer Center; Memorial Sloan Kettering Cancer Center; University of written permission of NCCN. Colorado Cancer Center; 12Dana-Farber/Brigham and Women’s Cancer Center; 13Duke Cancer Institute; 14Stanford Cancer Institute; 15University of Wisconsin Disclosures for the NCCN Hematopoietic Cell Carbone Cancer Center; 16Mayo Clinic Cancer Center; 17Abramson Cancer Transplantation Panel 18 Center at the University of Pennsylvania; The Sidney Kimmel Comprehensive At the beginning of each NCCN Guidelines Panel meeting, Cancer Center at Johns Hopkins; 19Fred Hutchinson Cancer Research Center/ fl 20 panel members review all potential con icts of interest. NCCN, Seattle Cancer Care Alliance; Robert H. Lurie Comprehensive Cancer Center in keeping with its commitment to public transparency, of Northwestern University; 21City of Hope National Medical Center; 22The 23 publishes these disclosures for panel members, staff, and University of Texas MD Anderson Cancer Center; Vanderbilt-Ingram Cancer NCCN itself. Center; 24Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 25Fox Chase Cancer Center; 26UC San Diego Individual disclosures for the NCCN Hematopoietic Cell Moores Cancer Center; and 27National Comprehensive Cancer Network Transplantation Panel members can be found on page 634. (The most recent version of these guidelines and accompanying *Discussion Writing Committee Member. disclosures are available at NCCN.org.) The complete and most recent version of these guidelines is See page 645 for related commentary. available free of charge at NCCN.org. JNCCN.org | Volume 18 Issue 5 | May 2020 599 NCCN GUIDELINES® Hematopoietic Cell Transplantation, Version 2.2020 Overview Marrow Transplant Research (CIBMTR) estimated that Hematopoietic cell transplantation (HCT) involves the 9,028 allogeneic transplants and 14,709 autologous trans- infusion of hematopoietic progenitor cells into patients plants were performed in the United States in 2018.4 Acute with malignant or nonmalignant hematologic disorders myeloid leukemia (AML), acute lymphocytic leukemia with the goal of re-establishing normal hematopoietic (ALL), and myelodysplastic syndromes (MDS) were and immune function.1,2 HCT is a potentially curative the most common malignancies treated with alloge- treatment option for patients with certain types of neic HCT, while autologous HCT was used most fre- hematologic malignancies and is also used to support quently in multiple myeloma, non-Hodgkin lymphoma, patients undergoing high-dose chemotherapy for the and Hodgkin lymphoma.4 treatment of certain solid tumors. HCT is classified as Outcomes of HCT vary according to the type and autologous or allogeneic based on the origin of he- stage of the disease being treated, the overall health of matopoietic cells. An autologous HCT uses the patient’s the patient, the degree of HLA-mismatch between donor own cells while an allogeneic HCT uses hematopoietic and recipient (for allogeneic HCT), and the source of cells from a human leukocyte antigen (HLA)-compatible the hematopoietic cells.2 Hematopoietic cells can be donor. Prior to HCT, most patients receive chemother- obtained from peripheral blood, BM, or umbilical cord apy, serotherapy, and/or radiation for pretransplant blood (UCB). Several clinical factors should be consid- conditioning (preparative regimen). In allogeneic HCT, ered when determining the optimal graft source for an in- preparative regimens are administered to eradicate dividual patient, including disease type, disease stage, patient malignant cells in the bone marrow (BM; if using comorbidities, and the urgency for transplantation.5 Mo- myeloablative regimen) and induce immunosuppres- bilization of peripheral blood progenitor cells (PBPCs) by sion so that engraftment of healthy donor cells occurs.1 granulocyte-colony stimulating factor has largely replaced In autologous HCT, high-dose myeloablative regimens use of BM grafts (in particular for autologous HCT) due to are used to treat the malignancy. This is followed by theeaseofcollection,avoidance of general anesthesia, rescue infusion of the patient’s own cells, which are more rapid engraftment rates, reduced risk of graft failure, harvested before high-dose therapy, to restore hema- and lower transplant-related mortality.6–8 However, allo- topoiesis and reconstitute the immune system. geneic PBPC transplants are associated with an increased The number of HCTs has increased in the United States risk of graft-versus-host disease (GVHD) compared with in recent years.3 The Center for International Blood and BM transplants.8,9 Allogeneic BM transplant continues to 600 © JNCCN—Journal of the National Comprehensive Cancer Network | Volume 18 Issue 5 | May 2020 Hematopoietic Cell Transplantation, Version 2.2020 NCCN GUIDELINES® be indicated in certain conditions such as severe aplastic Advances in HCT methods and supportive care have led anemia and other nonmalignant disorders, owing to a to improved survival after HCT.11 However, disease relapse lower risk of GVHD. Furthermore, several investigators and long-term complications continue to pose a major have advocated for the use of BM grafts for haploidentical threat to HCT survivors. Disease relapse is higher with ad- HCT10 and unrelated donor HCT.9 Advantages of using vanced disease and with the use of nonmyeloablative UCB grafts
Load more

Recommended publications
  • Pan-Canadian Pricing Alliance: Completed Negotiations
    Pan-Canadian Pricing Alliance: Completed Negotiations As of August 31, 2014 46 joint negotiations have been completed** for the following drugs and indications: Drug Product Indication/Use Brand Name (Generic Name) Please refer to individual jurisdictions for specific reimbursement criteria Adcetris (brentuximab) Used to treat lymphoma Afinitor (everolimus) Used to treat pancreatic neuroendocrine tumours, and to treat breast cancer Alimta (pemetrexed) Used to treat lung cancer (new indication) Used with ASA to prevent atherothrombotic events in patients with acute Brilinta (ticagrelor)† coronary syndrome Dificid Used to treat Clostridium difficile Used with ASA to prevent atherothrombotic events in patients with acute Effient (prasugrel) coronary syndrome Used to prevent strokes in patients with atrial fibrillation, and to prevent deep Eliquis (apixaban) vein thrombosis Erivedge (vismodegib) Used to treat metastatic basal cell carcinoma Esbriet (pirfenidone)* Used to treat idiopathic pulmonary fibrosis Galexos (simeprevir)* Used to treat chronic hepatitis C Genotype 1 infection Gilenya (fingolimod)† Used to treat relapsing-remitting multiple sclerosis Giotrif (afatinib) Used to treat EGFR mutation positive, advanced non-small cell lung cancer Halaven (eribulin) Used to treat breast cancer Inlyta Used to treat metastatic renal cell carcinoma Jakavi (ruxolitinib) Used to treat intermediate to high risk myelofibrosis Kadcyla (trastuzumab emtansine) Used to treat HER-2 positive metastatic breast cancer Kalydeco (ivacaftor) Used to treat cystic
    [Show full text]
  • Phase I-II Study of Ruxolitinib (INCB18424) for Patients With
    Protocol Page Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia (CML) with Minimal Residual Disease While on Therapy with Tyrosine Kinase Inhibitors 2012-0697 Core Protocol Information Short Title Ruxolitinib for CML with MRD Study Chair: Jorge Cortes Additional Contact: Allison Pike Rachel R. Abramowicz Leukemia Protocol Review Group Additional Memo Recipients: Recipients List OPR Recipients (for OPR use only) None Study Staff Recipients None Department: Leukemia Phone: 713-794-5783 Unit: 428 Study Manager: Allison Pike Full Title: Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia (CML) with Minimal Residual Disease While on Therapy with Tyrosine Kinase Inhibitors Public Description: Protocol Type: Standard Protocol Protocol Phase: Phase I/Phase II Version Status: Terminated 10/03/2019 Version: 24 Document Status: Saved as "Final" Submitted by: Rachel R. Abramowicz--5/7/2019 9:28:03 AM OPR Action: Accepted by: Amber M. Cumpian -- 5/8/2019 5:48:18 PM Which Committee will review this protocol? The Clinical Research Committee - (CRC) Protocol Body 2012-0697 April 6, 2015 Page 1 of 41 Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia (CML) with Minimal Residual Disease While on Therapy with Tyrosine Kinase Inhibitors Principal Investigator Jorge Cortes, MD Department of Leukemia MD Anderson Cancer Center 1515 Holcombe Blvd., Unit 428 Houston, TX 77030 (713)792-7305 Study Product: Ruxolitinib Protocol Number: 2012-0697 Coordinating Center: MD Anderson Cancer Center 1515 Holcombe Blvd., Unit 428 Houston, TX 77030 2012-0697 April 6, 2015 Page 2 of 41 1.
    [Show full text]
  • Summary Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211675Orig1s000 SUMMARY REVIEW Cross Discipline Team Leader Review NDA 211675 Division Director Sununa1y Rinvoq (upadacitinib) for RA Office Director Sununary AbbVie , Inc. DHHS/FDA/CDER/ODEII/DPARP Cross-Discipline Team Leader Review Division Director Summary Office Director Summary Date July 11 , 201 9 Rachel Glaser, MD, Clinical Team Leader, DPARP From Sally Seymour, MD, Director, DP ARP Marv Thanh Hai, MD, Acting Director, ODEII Cross-Discipline Team Leader Review Subject Division Director Summaiy Office Director Summary NDA/BLA # and Supplement# 211675 Applicant AbbVie fuc Date of Submission December 18, 201 8 PDUFA Goal Date AUITTlSt 18, 201 9 Proprietary Name RINVOO Established or Proper Name Uoadacitinib Dosa2e Form(s) 15 mg extended release tablets Applicant Proposed (b)(4 Indication(s )/Population(s) Applicant Proposed Dosing 15 mg orally administered once daily Reoimen(s) Recommendation on Regulatory Approval Action Recommended Treatment of adults with moderately to severely active lndication(s)/Population(s) (if rheumatoid ai1hritis who have had an inadequate aoolicable) resoonse or intolerance to methotrexate Recommended Dosing 15 mg orally administered once daily Re2imen(s) (if aoolicable) CDER Cross Discipline Team Leader Review Template 1 Version date: October 10, 2017fo r all NDAs and BLAs Reference ID: 4478224 Cross Discipline Team Leader Review NDA 211675 Division Director Summary Rinvoq (upadacitinib) for RA Office Director Summary AbbVie, Inc. DHHS/FDA/CDER/ODEII/DPARP 1. Benefit-Risk Assessment Benefit-Risk Assessment Framework Rheumatoid arthritis (RA) is a serious medical condition that affects over 1.3 million Americans. RA is a chronic progressive disease that primarily affects the joints, but can involve other organs.
    [Show full text]
  • Key Potential Drug Launches in 2021
    Key Potential Drug Launches in 2021 As a supplement to our well-known quarterly outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2021. These drugs represent new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare. The information in this presentation, including likelihood of approval (LOA) ratings and upcoming catalysts, is up to date as of June 2020. More details about each drug can be viewed instantly on Biomedtracker by clicking the icon. EXTRACT Contents This report covers the following indications: • Allergy • Hematology • Oncology • Psychiatry Atopic Dermatitis (Eczema) Anemia Due to Chronic Renal Failure Biliary Tract Cancer Attention Deficit Hyperactivity Pruritus Hemophilia Bladder Cancer Disorder (ADHD) Bone Marrow & Stem Cell Transplant Major Depressive Disorder • Autoimmune/Immunology (A&I) • Infectious Diseases (ID) Breast Cancer (MDD) Antineutrophil Cytoplasmic Antibodies Clostridium Difficile-Associated- Chronic Lymphocytic Leukemia (CLL) -(ANCA) Associated Vasculitis Diarrhea/Infection (CDAD/CDI) Cutaneous T-Cell Lymphoma (CTCL) • Renal Lupus Nephritis (LN) COVID-19 Diffuse Large B-Cell Lymphoma (DLBCL) Hyperoxaluria Myasthenia Gravis (MG) Pneumococcal Vaccines Follicular Lymphoma (FL) Psoriasis Seasonal Influenza Vaccines Marginal Zone Lymphoma (MZL) • Respiratory Ulcerative Colitis (UC) Melanoma Cystic Fibrosis • Metabolic
    [Show full text]
  • Imatinib (Gleevec™)
    Biologicals What Are They? When Did All of this Happen? There are Clear Benefits. Are there also Risks? Brian J Ward Research Institute of the McGill University Health Centre Global Health, Immunity & Infectious Diseases Grand Rounds – March 2016 Biologicals Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. National Cancer Institute (USA) What Effects Do Steroids Have on Immune Responses? This is your immune system on high dose steroids projects.accessatlanta.com • Suppress innate and adaptive responses • Shut down inflammatory responses in progress • Effects on neutrophils, macrophages & lymphocytes • Few problems because use typically short-term Virtually Every Cell and Pathway in Immune System ‘Target-able’ (Influenza Vaccination) Reed SG et al. Nature Medicine 2013 Nakaya HI et al. Nature Immunology 2011 Landscape - 2013 Antisense (30) Cell therapy (69) Gene Therapy (46) Monoclonal Antibodies (308) Recombinant Proteins (93) Vaccines (250) Other (81) http://www.phrma.org/sites/default/files/pdf/biologicsoverview2013.pdf Therapeutic Category Drugs versus Biologics Patented Ibuprofen (Advil™) Generic Ibuprofen BioSimilars/BioSuperiors ? www.drugbank.ca Patented Etanercept (Enbrel™) BioSimilar Etanercept Etacept™ (India) Biologics in Cancer Therapy Therapeutic Categories • Hormonal Therapy • Monoclonal antibodies • Cytokine therapy • Classical vaccine strategies • Adoptive T-cell or dendritic cells transfer • Oncolytic
    [Show full text]
  • Trastuzumab Emtansine > Printer-Friendly PDF
    Published on British Columbia Drug and Poison Information Centre (BC DPIC) ( http://www.dpic.org) Home > Drug Product Listings > Trastuzumab emtansine > Printer-friendly PDF Trastuzumab emtansine Trade Name: Kadcyla Manufacturer/Distributor: Hoffman-La Roche www.rochecanada.com 1-888-762-4388 Classification: Antineoplastic agent ATC Class: L01XC - other antineoplastic agents Status: active Notice of Compliance (yyyy/mm/dd): 2013/09/11 Date Marketed in Canada (yyyy/mm/dd): 2013/09/27 Presentation: Powder for injection: 20 mg/mL. DIN: 024121365 Comments: Kadcyla? is trastuzumab emtansine. It is a HER2-targeted antibody-drug conjugate for treatment of patients with HER2-positive, metastatic breast cancer who have received both prior treatment with Herceptin? (trastuzumab) and a taxane, separately or in combination. Kadcyla? is a different product from Herceptin?. Keywords: trastuzumab breast neoplasms Access: public Back to: Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database Status: <Any> ? Search Terms: Apply A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4) Date Marketed in Common Trade Generic Name Classification Canada Name(s) (yyyy/mm/dd) Apo- Chlorpropamide Antidiabetic agent 2017/02/01 chlorpropamide Cilazapril Inhibace ACE inhibitor Cladribine Mavenclad Immunosuppressant
    [Show full text]
  • Evaluation of Ruxolitinib and Pracinostat Combination As a Therapy for Patients with Myelofibrosis 2014-0445
    2014-0445 October 23, 2016 Page 1 Protocol Page EVALUATION OF RUXOLITINIB AND PRACINOSTAT COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS 2014-0445 Core Protocol Information Short Title Ruxolitinib and Pracinostat Combination Therapy for Patients with MF Study Chair: Srdan Verstovsek Additional Contact: Paula J. Cooley Sandra L. Rood Leukemia Protocol Review Group Department: Leukemia Phone: 713-792-7305 Unit: 428 Full Title: EVALUATION OF RUXOLITINIB AND PRACINOSTAT COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS Protocol Type: Standard Protocol Protocol Phase: Phase II Version Status: Terminated 06/01/2018 Version: 13 Submitted by: Sandra L. Rood--10/23/2017 2:12:37 PM OPR Action: Accepted by: Elizabeth Orozco -- 10/26/2017 1:34:18 PM Which Committee will review this protocol? The Clinical Research Committee - (CRC) 2014-0445 October 23, 2016 Page 2 Protocol Body EVALUATION OF RUXOLITINIB AND PRACINOSTAT COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS 1.0 HYPOTHESIS AND OBJECTIVES Hypothesis Ruxolitinib (also known as INCB018424), a JAK1/2 inhibitor, and pracinostat (a histone deacetylase inhibitor; HDACi) are effective and tolerable treatments for patients with myelofibrosis (MF). Combination of these agents in patients with MF can improve the overall clinical response to therapy without causing excessive toxicity. Objectives Primary: to determine the efficacy/clinical activity of the combination of ruxolitinib with pracinostat as therapy in patients with MF Secondary: to determine the toxicity of the combination of ruxolitinib with pracinostat as therapy in patients with MF Exploratory: to explore time to response and duration of response to explore changes in bone marrow fibrosis to explore changes in JAK2V617F (or other molecular marker) allele burden or changes in cytogenetic abnormalities 2.0 BACKGROUND AND RATIONALE 2.1 Myelofibrosis Myelofibrosis (MF) is a rare clonal proliferative disorder of a pluripotent stem cell.
    [Show full text]
  • Issue 18, July 2020 Newsletter
    Issue 18: July 2020 (Covering Dec 2019-Apr 2020 news) Special Update: COVID-19 and IBC Research Program and Clinic Operations The COVID-19 pandemic has had significant effects on the operations of our program and clinic. Starting in mid-March 2020, research and administrative staff began working 100% remotely to limit the on-site footprint and ensure the wellbeing of employees and patients. Physicians came to the hospital for their clinics and inpatient rotations, but otherwise worked remotely on their normal responsibilities in patient-care, research and administration. Meetings were all switched to Zoom, and we all learned how to function as remote teams. Clinical research required substantial changes to normal practices. Patients already enrolled on clinical trials continued to see physicians and receive treatment, however, new enrollments to our entire research portfolio were halted for 2+ months. Some patients had to receive infusions locally rather than traveling ot MD Anderson. Gradually, as the institutional restrictions opened up, as of July 2, we have now begun screening and enrolling new patients on all active IBC clinical trials, mindful of the need to push forward with providing the best treatment choices for patients diagnosed with this aggressive subtype of breast cancer. Throughout the pandemic, new IBC patients were seen in the IBC Multi-Team clinic on Wednesdays, and local new patients were also seen by the medical oncologists if they did not fit the multi-team criteria. Second-opinion (previously treated) patients from out of state were unable to be seen during the early part of the pandemic, but as of now, these patients are being accommodated due to the Breast Center being approved as a strategic service line for the institution.
    [Show full text]
  • The Janus Kinase Inhibitor Ruxolitinib Prevents Terminal Shock in a Mouse Model of Arenavirus Hemorrhagic Fever
    microorganisms Communication The Janus Kinase Inhibitor Ruxolitinib Prevents Terminal Shock in a Mouse Model of Arenavirus Hemorrhagic Fever Mehmet Sahin 1, Melissa M. Remy 1 , Doron Merkler 2 and Daniel D. Pinschewer 1,* 1 Department of Biomedicine—Haus Petersplatz, Division of Experimental Virology, University of Basel, 4009 Basel, Switzerland; [email protected] (M.S.); [email protected] (M.M.R.) 2 Department of Pathology and Immunology, Division of Clinical Pathology, University Hospital of Geneva, 1211 Geneva, Switzerland; [email protected] * Correspondence: [email protected] Abstract: Arenaviruses such as Lassa virus cause arenavirus hemorrhagic fever (AVHF), but pro- tective vaccines and effective antiviral therapy remain unmet medical needs. Our prior work has revealed that inducible nitric oxide synthase (iNOS) induction by IFN-γ represents a key pathway to microvascular leak and terminal shock in AVHF. Here we hypothesized that Ruxolitinib, an FDA- approved JAK inhibitor known to prevent IFN-γ signaling, could be repurposed for host-directed therapy in AVHF. We tested the efficacy of Ruxolitinib in MHC-humanized (HHD) mice, which develop Lassa fever-like disease upon infection with the monkey-pathogenic lymphocytic chori- omeningitis virus strain WE. Anti-TNF antibody therapy was tested as an alternative strategy owing to its expected effect on macrophage activation. Ruxolitinib but not anti-TNF antibody prevented hypothermia and terminal disease as well as pleural effusions and skin edema, which served as readouts of microvascular leak. As expected, neither treatment influenced viral loads. Intrigu- Citation: Sahin, M.; Remy, M.M.; ingly, however, and despite its potent disease-modifying activity, Ruxolitinib did not measurably Merkler, D.; Pinschewer, D.D.
    [Show full text]
  • Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer
    International Journal of Molecular Sciences Review Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer Hsing-Ju Wu 1,2,3 and Pei-Yi Chu 4,5,6,7,* 1 Department of Biology, National Changhua University of Education, Changhua 500, Taiwan; [email protected] 2 Research Assistant Center, Show Chwan Memorial Hospital, Changhua 500, Taiwan 3 Department of Medical Research, Chang Bing Show Chwan Memorial Hospital, Lukang Town, Changhua County 505, Taiwan 4 School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City 231, Taiwan 5 Department of Pathology, Show Chwan Memorial Hospital, No. 542, Sec. 1 Chung-Shan Rd., Changhua 500, Taiwan 6 Department of Health Food, Chung Chou University of Science and Technology, Changhua 510, Taiwan 7 National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan * Correspondence: [email protected]; Tel.: +886-975-611-855; Fax: +886-4-7227-116 Abstract: Breast cancer is the most commonly diagnosed cancer type and the leading cause of cancer-related mortality in women worldwide. Breast cancer is fairly heterogeneous and reveals six molecular subtypes: luminal A, luminal B, HER2+, basal-like subtype (ER−, PR−, and HER2−), normal breast-like, and claudin-low. Breast cancer screening and early diagnosis play critical roles in improving therapeutic outcomes and prognosis. Mammography is currently the main commercially available detection method for breast cancer; however, it has numerous limitations. Therefore, reliable noninvasive diagnostic and prognostic biomarkers are required. Biomarkers used in cancer range from macromolecules, such as DNA, RNA, and proteins, to whole cells.
    [Show full text]
  • Jakafi® (Ruxolitinib)
    Jakafi® (ruxolitinib) (Oral) Document Number: IC-0073 Last Review Date 06/03/2019 Date of Origin: 03/01/2012 Dates Reviewed: 12/2012, 03/2013, 02/2014, 08/2014, 12/2014, 10/2015, 10/2016, 10/2017, 10/2018, 06/2019 I. Length of Authorization Coverage will be provided for six months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [Pharmacy Benefit]: 5 mg tablets: 2 tablets per day 10 mg tablets: 2 tablets per day 15 mg tablets: 2 tablets per day 20 mg tablets: 2 tablets per day 25 mg tablets: 2 tablets per day B. Max Units (per dose and over time) [Medical Benefit]: Acute GVHD 20 mg per day All other indications 50 mg per day III. Initial Approval Criteria Patient is 18 or older (unless otherwise specified); AND Patient does not have an active infection, including clinically important localized infections; AND Myelofibrosis (MF) (including primary, post-polycythemia vera and post-essential thrombocythemia MF) † Patient has symptomatic low- to intermediate-risk disease ‡ ; OR Patient has intermediate to high-risk disease† ; AND 9 o Starting platelet count (<30 days old) is ≥ 50 X 10 /L; OR Proprietary & Confidential © 2019 Magellan Health, Inc. Patient has accelerated phase or blast phase/acute myeloid leukemia ‡ Polycythemia Vera† Patient has had an inadequate response (or intolerance) to a 3 month or longer trial of hydroxyurea † or interferon therapy ‡; AND o Patient has symptomatic low risk disease with indications for cytoreductive therapy; OR o Patient has high risk disease Acute Graft Versus Host Disease (aGVHD) † Patient age is 12 years or older; AND Patient has acute, steroid-refractory, grade II-IV disease; AND Therapy being used for disease related to allogeneic hematopoietic stem cell transplantation † FDA Approved Indication(s); ‡ Compendia Approved Indication(s) IV.
    [Show full text]
  • Study Protocol);
    MSB0010718C B9991007 Final Protocol Amendment 4, 13 November 2017 A PHASE 1 PHARMACOKINETIC−PHARMACODYNAMIC STUDY OF AVELUMAB (MSB0010718C) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED STAGE CLASSICAL HODGKIN’S LYMPHOMA JAVELIN HODGKIN’S Compound: MSB0010718C Compound Name: Avelumab United States (US) Investigational New CCI Drug (IND) Number: European Clinical Trials Database 2015-002636-41 (EudraCT) Number: Protocol Number: B9991007 Phase: 1 Page 1 MSB0010718C B9991007 Final Protocol Amendment 4, 13 November 2017 Document History Document Version Date Summary of Changes Protocol Amendment 4 13 November Added Section 3.1.3, Safety Stopping 2017 Rules, in Section 3, Study Design. Added Section 9.4.1, Safety Stopping Rules, in Section 9.4, Safety Analysis. Protocol Amendment 3 09 May 2017 Major changes to the expansion phase: Target population: only patients relapsing following a prior allogeneic hematopoietic stem cell transplant (HSCT) will be enrolled in the study, given the high response rate observed in the lead-in phase and the lack of licensed therapy for this subset of patients. Biopsy: introduction of baseline and on-treatment mandatory biopsies to ensure availability of tumor material, to assess pharmacodynamic effects, mechanism of action and patient stratification related to response. Criteria of disease response: change from Response Criteria for Malignant Lymphoma (Cheson et al., 2007) to Lugano Classification (Cheson et al., 2014) to reflect change in current clinical practice. Study Design: introduction of an intra-patient
    [Show full text]